76,350 Shares in Progyny, Inc. (NASDAQ:PGNY) Purchased by Aurora Investment Counsel

Aurora Investment Counsel acquired a new position in Progyny, Inc. (NASDAQ:PGNY - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 76,350 shares of the company's stock, valued at approximately $1,280,000. Aurora Investment Counsel owned 0.08% of Progyny as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. RiverPark Advisors LLC boosted its holdings in Progyny by 9.6% during the second quarter. RiverPark Advisors LLC now owns 5,408 shares of the company's stock worth $155,000 after buying an additional 474 shares during the last quarter. Arizona State Retirement System boosted its holdings in Progyny by 2.6% during the second quarter. Arizona State Retirement System now owns 24,313 shares of the company's stock worth $696,000 after buying an additional 609 shares during the last quarter. State of New Jersey Common Pension Fund D boosted its holdings in Progyny by 1.1% during the second quarter. State of New Jersey Common Pension Fund D now owns 70,717 shares of the company's stock worth $2,023,000 after buying an additional 787 shares during the last quarter. Quarry LP lifted its holdings in shares of Progyny by 1,900.0% during the 2nd quarter. Quarry LP now owns 880 shares of the company's stock valued at $25,000 after purchasing an additional 836 shares in the last quarter. Finally, Creative Planning lifted its holdings in shares of Progyny by 13.8% during the 2nd quarter. Creative Planning now owns 10,564 shares of the company's stock valued at $302,000 after purchasing an additional 1,283 shares in the last quarter. Institutional investors own 94.93% of the company's stock.

Progyny Stock Performance

NASDAQ:PGNY opened at $13.98 on Thursday. The stock has a fifty day moving average price of $16.74 and a 200-day moving average price of $22.92. The company has a market cap of $1.19 billion, a price-to-earnings ratio of 24.10, a PEG ratio of 1.65 and a beta of 1.44. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $42.08.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.26). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business had revenue of $286.63 million for the quarter, compared to the consensus estimate of $296.85 million. During the same quarter in the prior year, the company earned $0.16 earnings per share. Progyny's quarterly revenue was up 2.0% compared to the same quarter last year. Research analysts predict that Progyny, Inc. will post 0.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Barclays cut their price objective on Progyny from $30.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, November 14th. JMP Securities cut Progyny from an "outperform" rating to a "market perform" rating in a report on Thursday, September 19th. Leerink Partnrs cut Progyny from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 7th. Canaccord Genuity Group cut Progyny from a "buy" rating to a "hold" rating and cut their price objective for the company from $37.00 to $24.00 in a report on Wednesday, August 7th. Finally, Canaccord Genuity Group cut their target price on Progyny from $18.00 to $17.00 and set a "hold" rating on the stock in a research note on Wednesday, November 13th. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $25.42.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.